| Drug
Information |
| Name | CGS-27023A |
| Indication | Not Available | Experimental |
| Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format
|
| InChI | 1S/C18H23N3O5S/c1-13(2)17(18(22)20-23)21(12-14-5-4-10-19-11-14)27
(24,25)16-8-6-15(26-3)7-9-16/h4-11,13,17,23H,12H2,1-3H3,(H,20,22)
/t17-/m1/s1 |
| InChIKey | BSIZUMJRKYHEBR-QGZVFWFLSA-N |
| Canonical SMILES | CC(C)C(C(=O)NO)N(CC1=CN=CC=C1)S(=O)(=O)C2=CC=C(C=C2)OC |
| Isomeric SMILES | CC(C)[C@H](C(=O)NO)N(CC1=CN=CC=C1)S(=O)(=O)C2=CC=C(C=C2)OC |
| Target | ADAMTS4 |  | Inhibitor | [1] |
| Anthrax lethal factor | | Inhibitor | [2] |
| Carbonic anhydrase II | | Inhibitor | [3] |
| Carbonic anhydrase IX | | Inhibitor | [3] |
| Matrix metalloproteinase 13 | | Inhibitor | [4] |
| Matrix metalloproteinase 14 | | Inhibitor | [5] |
| Matrix metalloproteinase 3 | | Inhibitor | [6] |
| Matrix metalloproteinase 7 | | Inhibitor | [5] |
| Matrix metalloproteinase 8 | | Inhibitor | [7] |
| Matrix metalloproteinase 9 | | Inhibitor | [8] |
| Matrix metalloproteinase-1 | | Inhibitor | [2] |
| Matrix metalloproteinase-2 | | Inhibitor | [8] |
| Ref 1 | Bioorg Med Chem Lett. 2006 Jan 15;16(2):311-6. Epub 2005 Nov 3.Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. To Reference |
| Ref 2 | Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8. Epub 2005 Dec 9.The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. To Reference |
| Ref 3 | Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. Epub 2007 Jan 19.Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. To Reference |
| Ref 4 | Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13.Heterocycle-based MMP inhibitors with P2' substituents. To Reference |
| Ref 5 | Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. Epub 2006 Nov 14.Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. To Reference |
| Ref 6 | Bioorg Med Chem Lett. 2005 Mar 1;15(5):1321-6.N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. To Reference |
| Ref 7 | J Med Chem. 1999 Nov 4;42(22):4547-62.Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. To Reference |
| Ref 8 | Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6.Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. To Reference |
